drugset / Trial / NCT01626872

Long-Term Study of MP-214 in Patients With Schizophrenia

NCT01626872

Phase 2/3 Completed 254 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.

Timeline

Start
2012-09
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 3 mg
Subject Cariprazine Small molecule 6 mg
Subject Cariprazine Small molecule 9 mg
Comparator Risperidone Other / unclassified 4 mg

Indications